Publication date: Aug 01, 2026
This study investigates the adjunctive effects of mindfulness-based cognitive therapy (MBCT) combined with escitalopram hydrobromide on cognitive function and emotional well-being in older adults with treatment-resistant depression (TRD). We hypothesized that this combined approach would lead to greater enhancements in cognitive abilities and overall well-being compared to escitalopram hydrobromide alone in this vulnerable population. A total of 230 older adults with TRD and cognitive impairment were randomly assigned into two groups: an experimental group receiving MBCT plus escitalopram (n = 115) and a control group receiving escitalopram alone (n = 115). Cognitive function, depression severity, and quality of life were assessed at baseline, 6 weeks, and 12 weeks using the Montreal Cognitive Assessment (MoCA), Hamilton Depression Rating Scale (HAM-D), and General Quality of Life Index-74 (GQOLI-74). The experimental group demonstrated significant improvements in cognitive function (MoCA scores) and quality of life (GQOLI-74 scores) compared to the control group at both 6 and 12 weeks (p
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Escitalopram |
| disease | MESH | cognitive impairment |
| disease | MESH | HAM |
| disease | MESH | refractory depression |
| drug | DRUGBANK | Citalopram |